HGH Fragment 176-191
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
HGH Fragment 176-191 is listed as gh fragment / lipolytic.
- •Fat loss (research)
- •Body recomposition
Regulatory status: Research chemical — not approved for human use.
Structure & Properties
Compound: HGH Fragment 176-191; also known as Frag 176-191, Lipolytic fragment.
Pharmacologic class: GH Fragment / Lipolytic.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
C-terminal fragment of hGH that stimulates beta-3 adrenergic lipolysis in adipocytes without measurable effect on IGF-1 or glucose.
- •Targeted lipolysis without GH-like glucose effects
- •No reported IGF-1 elevation
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Early human trials of AOD-9604 analog failed to beat placebo
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
No strict time-of-day requirement. Dose consistently at the same time daily and rotate injection sites. Follow the per-peptide dosing section above.
Potential interactions and combinations to avoid
- •Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- •Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Injection-site reactions
- •Unproven efficacy in humans
- •Unregulated purity
Contraindications
- •Pregnancy or breastfeeding
- •Unknown safety in malignancy
- •Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- •Active or untreated diabetic retinopathy
- •Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- •Untreated hypothyroidism or uncorrected adrenal insufficiency
- •Acromegaly, pituitary adenoma, or intracranial hypertension
- •Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- •Critical illness after acute surgery, trauma, or respiratory failure
- •Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 200–500 mcg/day
Frequency: 1–2× daily, fasted
Cycling: Commonly 8–12 weeks fasted-morning dosing, then a 4-week break.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is HGH Fragment 176-191?
In plain words
HGH Fragment 176-191 is a small piece of human growth hormone. It stimulates fat breakdown in fat cells without measurable changes in blood sugar or IGF-1 [a growth-related protein]. Researchers study it for possible fat loss, but its effectiveness in humans is unproven. It is not approved for human use, and concerns include reactions where it is injected and unregulated purity.
Technical definition
HGH Fragment 176-191 is a peptide corresponding to the C-terminal amino acids 176–191 of human growth hormone (hGH). It stimulates beta-3 adrenergic receptor–mediated lipolysis in adipocytes without measurable effects on IGF-1 or glucose. Evidence is preclinical or observational; it is a research chemical that is not FDA-approved or approved for human use.
Function
Dosing
Recommended Time of Day
Morning fasted, and/or 30 min before cardio — always away from food.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Commonly 8–12 weeks fasted-morning dosing, then a 4-week break.
Timing & Interactions
- ·Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- ·Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
- ·Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on HGH Fragment 176-191 and sync them to Vial Lab.
Benefits
- ·Targeted lipolysis without GH-like glucose effects
- ·No reported IGF-1 elevation
Risks
- ·Injection-site reactions
- ·Unproven efficacy in humans
- ·Unregulated purity
Contraindications
- ·Pregnancy or breastfeeding
- ·Unknown safety in malignancy
- ·Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- ·Active or untreated diabetic retinopathy
- ·Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- ·Untreated hypothyroidism or uncorrected adrenal insufficiency
- ·Acromegaly, pituitary adenoma, or intracranial hypertension
- ·Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- ·Critical illness after acute surgery, trauma, or respiratory failure
- ·Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Research chemical — not approved for human use
Veterinary Use (Pets)
No established veterinary protocol for HGH Fragment 176-191. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →